Ophthalix Inc (OPLI) 1.0100 $OPLI
Global Uveitis Market 2014-2018
M2 - Mon Jun 23, 4:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3f25wz/global_uveitis) has announced the addition of the "Global Uveitis Market 2014-2018" report to their offering. Currently, the current competition in the Global Uveitis market is weak and the available treatment options have only been moderately successful in meeting market demand. The current market is served in the main by three approved products namely Alcon Laboratories's Durezol, Allergan's Ozurdex, and Bausch & Lomb's Retisert. The expected entry of new players such as Lux Biosciences's Luveniq (NDA filled), pSivida Corp.'s Medidur (phase III), and Santen Pharmaceutical Co. Ltd.'s DE-109 (phase III) within the forecast period is expected to intensify the competition in future. The products currently available in the market are associated with low safety and as those products do not serve the market's unmet need, the market continues to present opportunities for stronger pipeline candidates. According to the report, one of the main drivers in this market is the increasing prevalence of eye disorders around the world, which has consequently led to a rise in the incidence of uveitis. Uveitis is responsible for approximately 5 to 20 percent of legal blindness in western countries and approximately 25 percent of blindness in the developing world. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Treatment Options for Uveitis 09. Pipeline Snapshot 10. Rate of Incidence and Prevalence 11. Geographical Segmentation 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Vendor Landscape 20. Key Vendor Analysis 21. Other Reports in this Series Companies Mentioned: - Abbvie Inc. - Alcon Laboratories Inc. - Allergan Inc. - Bausch & Lomb Inc. - Artielle ImmunoTherapeutics Inc. - Enzo Biochem Inc. - Hanall Pharmaceutical Co. Ltd. - Lux Biosciences Inc. - OphthaliX Inc. - Regeneron Pharmaceuticals Inc. - TopiVertLtd. - pSivida Corp. - XOMA Corp. - Santen Pharmaceutical Co. For more information visit http://www.researchandmarkets.com/research/3f...al_uveitis
Can-Fite Files 2013 Annual Report on Form 20-F
PR Newswire - Mon Mar 31, 1:28PM CDT
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company's complete audited financial statements, free of charge. Requests can be made by contacting Can-Fite Investor Relations at 10 Bareket Street, Kiryat Matalon, Petah-Tikva 4951778, Israel or by phone at +972-3-9241114.
Can-Fite to Present at the 9th International Congress of Autoimmunity
PR Newswire - Tue Mar 25, 6:00AM CDT
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 9th International Congress of Autoimmunity. The conference will be held on March 26-30, 2014 at Nice Acropolis Convention Center in Nice, France.
Can-Fite: Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel
PR Newswire - Mon Mar 17, 6:00AM CDT
Can-Fite BioPharma (TASE: CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 has been approved by the Institutional Review Board (IRB) in Israel.
Can-Fite Completes $5 Million Private Placement
PR Newswire - Mon Mar 10, 11:44AM CDT
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has closed a private placement with mostly US healthcare focused institutional investors resulting in gross proceeds of $5 million.
Can-Fite Announces the Addition of A Key Opinion Leader to Boost its Rheumatoid Arthritis CF101 Program
PR Newswire - Mon Mar 03, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the addition of a key opinion leader, medical and industry expert, Dr. Lee S. Simon, as consultant to assist in the regulatory and clinical development of the company's CF101 rheumatoid arthritis program.
Can-Fite to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Thu Feb 27, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 26th Annual ROTH Conference. The conference will be held on March 9-12, 2014 at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Can-Fite Granted Patent on the Manufacturing of CF101 in Japan
PR Newswire - Tue Feb 25, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Japan Patent Office (JPO) has granted a Japanese patent which bears the Patent No. 5467872 and is titled "Process for the Synthesis of IB-MECA". This patent describes a method for the chemical synthesis of the A3 adenosine receptor agonist, IB-MECA, which is the active pharmaceuticals ingredient (API) of the CF101 drug candidate. Under its patent rights, Can-Fite will have exclusive rights for the manufacturing of CF101 in Japan till 2028.
Can-Fite Provides Update on Key Milestones for 2014
PR Newswire - Tue Feb 18, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's development plan for 2014.
Can-Fite Comments on Global Rheumatoid Arthritis Market Opportunity
PR Newswire - Tue Feb 11, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today commented on the overall growth of the global rheumatoid arthritis market opportunity and the potential impact for the Company's proprietary drug CF101.
Can-Fite Submitted Phase II Study Protocol with CF102 to Treat Patients with Advanced Liver Cancer
PR Newswire - Thu Feb 06, 6:00AM CST
Can-Fite BioPharma (TASE: CFBI), (OTC: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 drug candidate has been submitted.
Can-Fite to Present at Two Upcoming Healthcare Investor Conferences
PR Newswire - Tue Jan 07, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF), (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that it is scheduled to present at two upcoming healthcare investor conferences in San Francisco, California.
OphthaliX to Retrospectively Analyze Phase III Dry Eye Syndrome Study Data Based on A3 Adenosine Receptor Biomarker
PR Newswire - Tue Dec 31, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the following:
OphthaliX to Conduct a Retrospective Analysis of the Phase III Dry Eye Syndrome Study Data Based on the A3 Adenosine Receptor Biomarker
PR Newswire - Tue Dec 31, 6:00AM CST
OphthaliX Inc. (OTCQB: OPLI), announced today that it will conduct a retrospective analysis of the Phase III Dry Eye Syndrome study data to determine if there is a correlation between the CF101 target, the A3 adenosine receptor, expression and patients' response to the drug. This analysis is based on recent positive data from a Phase IIb Rheumatoid Arthritis study of CF101 conducted by OphthaliX's parent company, Can-Fite BioPharma Ltd., where patients were enrolled based on the expression level of the A3 adenosine receptor biomarker.
OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome
PR Newswire - Mon Dec 30, 12:30AM CST
OphthaliX Inc. (OTCQB: OPLI), announced today results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist. The patients were randomized to receive two oral doses of CF101 (0.1 mg or 1.0 mg) or a placebo, for a period of 24 weeks.
Can-Fite Granted U.S. Patent for Utilization of A3 Adenosine Receptor as Biomarker to Predict Patient Response to CF101 in Autoimmune Inflammatory Indications
PR Newswire - Thu Dec 19, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today, that the U.S. Patent and Trademark Office granted the Company a patent which bears the Patent No. 8,541,182 and is titled "A Biological Marker for Inflammation". The patent was granted on September 24, 2013 and will be valid until 2026, protecting Can-Fite's findings relating to the utilization of the A3 Adenosine Receptor ("A3AR"
as a biomarker to predict patients' response to CF101 in autoimmune inflammatory indications.
OphthaliX to Initiate a Phase II study of CF101 for the Treatment of Uveitis
PR Newswire - Tue Jul 16, 4:44PM CDT
OphthaliX Inc. (OTC BB: OPLI), announced today the submission of a Phase II study protocol of its drug candidate, CF101, for the treatment of uveitis. The Phase II study will be conducted in Europe and Israel and will investigate the efficacy and safety of CF101 in 45 patients with active, sight-threatening, noninfectious intermediate or posterior uveitis, who will be treated with either CF101 or a placebo for a period of six months.
OphthaliX Inc names Dr Michael Belkin to board
M2 - Wed Jul 03, 3:47AM CDT
Biopharmaceutical company OphthaliX Inc (OTC BB:OPLI) announced on Tuesday that it has appointed Dr Michael Belkin to its board of directors.
OphthaliX Appoints Dr. Michael Belkin to its Board of Directors
PR Newswire - Tue Jul 02, 6:42PM CDT
OphthaliX, Inc. (OTC BB: OPLI), is pleased to announce the appointment of Dr. Michael Belkin to the Company's Board of Directors. Dr. Michael Belkin is a Professor of Ophthalmology at Tel Aviv University in Tel Aviv, Israel, and the Director of the Ophthalmic Technologies Laboratory at the university's Eye Research Institute at the Sheba Medical Center. He was awarded a master's degree in natural sciences by Cambridge University, England, and received a doctorate in medicine from the Hebrew University of Jerusalem. Dr. Belkin served previously as Director of Research, Development and Non-Conventional Warfare Medicine in the Israel Defense Forces Medical Corps. He was also the first full-time Director of the Tel Aviv University Eye Research Institute, Chairman of the Tel-Aviv University Department of Ophthalmology and the President of the Israel Society of Eye and Vision Research, of which he was one of the founders.
Global Uveitis Market 2014-2018
M2 - Mon Jun 23, 4:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3f25wz/global_uveitis) has announced the addition of the "Global Uveitis Market 2014-2018" report to their offering. Currently, the current competition in the Global Uveitis market is weak and the available treatment options have only been moderately successful in meeting market demand. The current market is served in the main by three approved products namely Alcon Laboratories's Durezol, Allergan's Ozurdex, and Bausch & Lomb's Retisert. The expected entry of new players such as Lux Biosciences's Luveniq (NDA filled), pSivida Corp.'s Medidur (phase III), and Santen Pharmaceutical Co. Ltd.'s DE-109 (phase III) within the forecast period is expected to intensify the competition in future. The products currently available in the market are associated with low safety and as those products do not serve the market's unmet need, the market continues to present opportunities for stronger pipeline candidates. According to the report, one of the main drivers in this market is the increasing prevalence of eye disorders around the world, which has consequently led to a rise in the incidence of uveitis. Uveitis is responsible for approximately 5 to 20 percent of legal blindness in western countries and approximately 25 percent of blindness in the developing world. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Market Landscape 08. Treatment Options for Uveitis 09. Pipeline Snapshot 10. Rate of Incidence and Prevalence 11. Geographical Segmentation 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Vendor Landscape 20. Key Vendor Analysis 21. Other Reports in this Series Companies Mentioned: - Abbvie Inc. - Alcon Laboratories Inc. - Allergan Inc. - Bausch & Lomb Inc. - Artielle ImmunoTherapeutics Inc. - Enzo Biochem Inc. - Hanall Pharmaceutical Co. Ltd. - Lux Biosciences Inc. - OphthaliX Inc. - Regeneron Pharmaceuticals Inc. - TopiVertLtd. - pSivida Corp. - XOMA Corp. - Santen Pharmaceutical Co. For more information visit http://www.researchandmarkets.com/research/3f...al_uveitis
Can-Fite Files 2013 Annual Report on Form 20-F
PR Newswire - Mon Mar 31, 1:28PM CDT
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company's complete audited financial statements, free of charge. Requests can be made by contacting Can-Fite Investor Relations at 10 Bareket Street, Kiryat Matalon, Petah-Tikva 4951778, Israel or by phone at +972-3-9241114.
Can-Fite to Present at the 9th International Congress of Autoimmunity
PR Newswire - Tue Mar 25, 6:00AM CDT
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 9th International Congress of Autoimmunity. The conference will be held on March 26-30, 2014 at Nice Acropolis Convention Center in Nice, France.
Can-Fite: Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel
PR Newswire - Mon Mar 17, 6:00AM CDT
Can-Fite BioPharma (TASE: CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 has been approved by the Institutional Review Board (IRB) in Israel.
Can-Fite Completes $5 Million Private Placement
PR Newswire - Mon Mar 10, 11:44AM CDT
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has closed a private placement with mostly US healthcare focused institutional investors resulting in gross proceeds of $5 million.
Can-Fite Announces the Addition of A Key Opinion Leader to Boost its Rheumatoid Arthritis CF101 Program
PR Newswire - Mon Mar 03, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the addition of a key opinion leader, medical and industry expert, Dr. Lee S. Simon, as consultant to assist in the regulatory and clinical development of the company's CF101 rheumatoid arthritis program.
Can-Fite to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Thu Feb 27, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 26th Annual ROTH Conference. The conference will be held on March 9-12, 2014 at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Can-Fite Granted Patent on the Manufacturing of CF101 in Japan
PR Newswire - Tue Feb 25, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Japan Patent Office (JPO) has granted a Japanese patent which bears the Patent No. 5467872 and is titled "Process for the Synthesis of IB-MECA". This patent describes a method for the chemical synthesis of the A3 adenosine receptor agonist, IB-MECA, which is the active pharmaceuticals ingredient (API) of the CF101 drug candidate. Under its patent rights, Can-Fite will have exclusive rights for the manufacturing of CF101 in Japan till 2028.
Can-Fite Provides Update on Key Milestones for 2014
PR Newswire - Tue Feb 18, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's development plan for 2014.
Can-Fite Comments on Global Rheumatoid Arthritis Market Opportunity
PR Newswire - Tue Feb 11, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today commented on the overall growth of the global rheumatoid arthritis market opportunity and the potential impact for the Company's proprietary drug CF101.
Can-Fite Submitted Phase II Study Protocol with CF102 to Treat Patients with Advanced Liver Cancer
PR Newswire - Thu Feb 06, 6:00AM CST
Can-Fite BioPharma (TASE: CFBI), (OTC: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 drug candidate has been submitted.
Can-Fite to Present at Two Upcoming Healthcare Investor Conferences
PR Newswire - Tue Jan 07, 6:00AM CST
Can-Fite BioPharma Ltd. (NYSE MKT: CANF), (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that it is scheduled to present at two upcoming healthcare investor conferences in San Francisco, California.
OphthaliX to Retrospectively Analyze Phase III Dry Eye Syndrome Study Data Based on A3 Adenosine Receptor Biomarker
PR Newswire - Tue Dec 31, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the following:
OphthaliX to Conduct a Retrospective Analysis of the Phase III Dry Eye Syndrome Study Data Based on the A3 Adenosine Receptor Biomarker
PR Newswire - Tue Dec 31, 6:00AM CST
OphthaliX Inc. (OTCQB: OPLI), announced today that it will conduct a retrospective analysis of the Phase III Dry Eye Syndrome study data to determine if there is a correlation between the CF101 target, the A3 adenosine receptor, expression and patients' response to the drug. This analysis is based on recent positive data from a Phase IIb Rheumatoid Arthritis study of CF101 conducted by OphthaliX's parent company, Can-Fite BioPharma Ltd., where patients were enrolled based on the expression level of the A3 adenosine receptor biomarker.
OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome
PR Newswire - Mon Dec 30, 12:30AM CST
OphthaliX Inc. (OTCQB: OPLI), announced today results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist. The patients were randomized to receive two oral doses of CF101 (0.1 mg or 1.0 mg) or a placebo, for a period of 24 weeks.
Can-Fite Granted U.S. Patent for Utilization of A3 Adenosine Receptor as Biomarker to Predict Patient Response to CF101 in Autoimmune Inflammatory Indications
PR Newswire - Thu Dec 19, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today, that the U.S. Patent and Trademark Office granted the Company a patent which bears the Patent No. 8,541,182 and is titled "A Biological Marker for Inflammation". The patent was granted on September 24, 2013 and will be valid until 2026, protecting Can-Fite's findings relating to the utilization of the A3 Adenosine Receptor ("A3AR"
as a biomarker to predict patients' response to CF101 in autoimmune inflammatory indications. OphthaliX to Initiate a Phase II study of CF101 for the Treatment of Uveitis
PR Newswire - Tue Jul 16, 4:44PM CDT
OphthaliX Inc. (OTC BB: OPLI), announced today the submission of a Phase II study protocol of its drug candidate, CF101, for the treatment of uveitis. The Phase II study will be conducted in Europe and Israel and will investigate the efficacy and safety of CF101 in 45 patients with active, sight-threatening, noninfectious intermediate or posterior uveitis, who will be treated with either CF101 or a placebo for a period of six months.
OphthaliX Inc names Dr Michael Belkin to board
M2 - Wed Jul 03, 3:47AM CDT
Biopharmaceutical company OphthaliX Inc (OTC BB:OPLI) announced on Tuesday that it has appointed Dr Michael Belkin to its board of directors.
OphthaliX Appoints Dr. Michael Belkin to its Board of Directors
PR Newswire - Tue Jul 02, 6:42PM CDT
OphthaliX, Inc. (OTC BB: OPLI), is pleased to announce the appointment of Dr. Michael Belkin to the Company's Board of Directors. Dr. Michael Belkin is a Professor of Ophthalmology at Tel Aviv University in Tel Aviv, Israel, and the Director of the Ophthalmic Technologies Laboratory at the university's Eye Research Institute at the Sheba Medical Center. He was awarded a master's degree in natural sciences by Cambridge University, England, and received a doctorate in medicine from the Hebrew University of Jerusalem. Dr. Belkin served previously as Director of Research, Development and Non-Conventional Warfare Medicine in the Israel Defense Forces Medical Corps. He was also the first full-time Director of the Tel Aviv University Eye Research Institute, Chairman of the Tel-Aviv University Department of Ophthalmology and the President of the Israel Society of Eye and Vision Research, of which he was one of the founders.
